Single-Cell Polyfunctional Strength Applied to Checkpoint & Antibody Based Immunotherapies

Proteomics

Single-Cell Polyfunctional Strength Applied to Checkpoint & Antibody Based Immunotherapies

Featured Speaker: Will Singleterry, PhD, Director of Business Development, IsoPlexis

Your data is secure

We keep your personal information safe and do not share it with any third parties. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy. You may unsubscribe at any time.

What's Inside

In this Webinar we discuss:

Evaluate T cell responses induced by various bispecific T cell engagers across phenotypes

Understand the heterogeneity of TIL polyfunctionality in solid tumors in response to checkpoint inhibitors

Uniquely correlate clinical anti-tumor responses with IsoPlexis data

Optimize combination cancer vaccines in melanoma using model systems

Explore Related Resources

Access related webinars, eBooks, app notes & case studies.

Webinar

Biomarker Strategies for Optimizing Checkpoint Immunotherapy Treatment

Blog

Checkpoint Immunotherapy in Solid Tumor Is Evolving: Advancing Cellular Fitness & Precision Medicine with IsoPlexis’ Platform

Application Highlight

Employing PSI™ to Identify Optimal Bi-Specific Antibody Candidates

Watch the Webinar

Back to the Top